Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours

12 novembre 2026 aggiornato da: GlaxoSmithKline

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5864399 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Selected Advanced Solid Tumours

This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

155

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Is at least 18 years of age or the legal age of consent.

  • Has histologically confirmed unresectable metastatic disease of either:

    • colorectal cancer that has progressed through at least 2 prior lines of systemic therapy
    • non-small cell lung cancer that has progressed through at least 1 prior line of systemic therapy
  • Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.

  • Participants must provide Formalin-Fixed, Paraffin-Embedded (FFPE) tumour tissue sample taken from primary cancer or metastatic site.

  • Is willing to use adequate contraception.

  • Is capable of giving signed informed consent.

  • Has an ECOG performance status of 0 or 1.

  • Has adequate organ function.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria

  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months (with some exceptions).

  • Has had any major surgery within 28 days prior to first dose.

  • Has any history of prior allogeneic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • Has known active infectious disease or a serious infection within 4 weeks prior to the first dose.

  • Has a history (in prior year) of clinically significant or uncontrolled cardiovascular disease.

  • Has untreated brain or Central Nervous System (CNS) metastases or brain/CNS metastases that have progressed.

  • Any evidence of small cell or sarcomatoid histology for the NSCLC participants.

  • Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.

  • Has any active renal condition.

  • Has a history of discontinuing prior treatment due to TEAE of ILD/pneumonitis

  • Has a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis that required active treatment within 4 weeks before study-intervention administration.

  • Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy (with some exclusions).

  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

  • Has symptomatic and/or progressive pleural metastases or cytologically confirmed malignant pleural effusions despite appropriate analgesia and thoracenteses respectively. Participants with previously treated pleural metastases/malignant pleural effusions with clinical stability demonstrated for at least 4 weeks prior to first dose are not excluded from participation.

  • Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long term [30 days or longer]).

  • Has received any prior therapy targeting CEACAM5.

  • Has received any live vaccine within 30 days of first dose. Vaccination against COVID-19 using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary. Messenger Ribonucleic acid (mRNA) and adenoviral-based COVID-19 vaccines are considered non-live. If a COVID-19 vaccine is administered at any time, the date of COVID-19 vaccination must be entered in the electronic Case Report Form (eCRF).

  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before first dose.

  • History of local radiotherapy within 2 weeks prior to the first dose of study intervention; more than 30% of bone marrow irradiation or extensive radiotherapy within 4 weeks before the first dose of study intervention.

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent within 4 weeks prior to first dose. Participation in study follow-up part without IMP administration, non-interventional registry or epidemiological study is allowed.

  • Has a known Human Immunodeficiency Virus (HIV) infection AND meets at least one of the following criteria:

    • Has documented evidence of plasma HIV-1 Ribonucleic Acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    • Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    • Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    • Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in full protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    • Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    • Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening. Participants with history of CDC Stage 3 disease (also known as AIDS defining disease are eligible provided all other applicable criteria are met) if the AIDS-defining disease has been treated and cured or is stable for at least 3 months prior to screening. Cutaneous Karposi's Sarcoma not requiring systemic therapy is not exclusionary.
  • Is unable to adhere to the protocol-defined schedule of assessments, including requirements for the follow-up period of the study.

  • Has an Alanine Aminotransferase (ALT) or AST value >2.5x Upper Limit of Normal (ULN) and/or for participants with documented liver metastases/tumour infiltration has an ALT or AST value >5x ULN.

  • Has a total bilirubin value >1.5x ULN. Participants with Gilbert's syndrome can be included with a total bilirubin value >1.5x ULN, provided direct bilirubin is ≤1.5x ULN and participant otherwise meets entry criteria.

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. Stable noncirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if the participant otherwise meets entry criteria.

  • Has documented presence of Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention. In Japan, the following modification is applied; Has documented presence of HBsAg, HBcAb, or Hepatitis B surface antibody (HBsAb) (except for presence of HBsAb attributable to previous vaccination) at screening or within 3 months prior to the first dose of study intervention. For participants with presence of HBsAb, Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) will be tested every 3 months.

  • Has a positive Hepatitis C Virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV RNA is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment. Participants with a positive HCV antibody test result due to prior resolved disease, including those who have undergone curative HCV treatment, can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria.

  • Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention. The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.

  • Has baseline QT interval corrected for heart rate (QTc)>480 msec.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Parte 1: aumento della dose

GSK5864399 will be administered

Sperimentale: Parte 2: espansione della dose

GSK5864399 will be administered

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with changes in safety parameters
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severity
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with AEs leading to dose modifications
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in body weight
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Lasso di tempo: Up to approximately 155 weeks
Up to approximately 155 weeks
Part 2: Confirmed Objective Response Rate (cORR)
Lasso di tempo: Up to approximately 155 weeks

cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.

Up to approximately 155 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1& 2: Maximum concentration (Cmax) of GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Time to maximum concentration (Tmax) of GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Area under the concentration-time curve (AUC) of GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1& 2: Trough concentration (Ctrough) of GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks
Part 2: Progression-free survival (PFS)
Lasso di tempo: Up to approximately 161 weeks

PFS is defined as the time from date of randomization until the earliest date of documented disease progression as assessed by the Investigator according to RECIST1.1 or death due to any cause.

Up to approximately 161 weeks
Part 2: Duration of Response (DoR)
Lasso di tempo: Up to approximately 161 weeks

DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by the Investigator according to RECIST1.1) until the date of the first documented progression of disease (PD) or death, whichever is earlier.

Up to approximately 161 weeks
Part 1 & 2: Number of participants with Anti-drug antibodies (ADA) against GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks
Part 1 & 2: Titers of ADA against GSK5864399
Lasso di tempo: Up to approximately 161 weeks
Up to approximately 161 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

25 novembre 2026

Completamento primario (Stimato)

16 novembre 2029

Completamento dello studio (Stimato)

28 dicembre 2029

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Periodo di condivisione IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Criteri di accesso alla condivisione IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi